PGEN Overview

Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company developing gene and cell therapies for improving outcomes for patients with unmet medical needs. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.

Wall Street analysts forecast PGEN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PGEN is9.00 USD with a low forecast of 9.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Precigen Inc revenue for the last quarter amounts to 2.92M USD, increased 206.61

Precigen Inc. EPS for the last quarter amounts to -1.06 USD, increased 1077.78

Precigen Inc (PGEN) has 143 emplpoyees as of March 11 2026.

Today PGEN has the market capitalization of 1.24B USD.